[go: up one dir, main page]

BR0309357A - Método para fabricar cristais de esteróides, cristais obtìveis de acordo com esse método, e formulações farmacêuticas - Google Patents

Método para fabricar cristais de esteróides, cristais obtìveis de acordo com esse método, e formulações farmacêuticas

Info

Publication number
BR0309357A
BR0309357A BR0309357-3A BR0309357A BR0309357A BR 0309357 A BR0309357 A BR 0309357A BR 0309357 A BR0309357 A BR 0309357A BR 0309357 A BR0309357 A BR 0309357A
Authority
BR
Brazil
Prior art keywords
crystals
pharmaceutical formulations
obtainable
steroid
particle size
Prior art date
Application number
BR0309357-3A
Other languages
English (en)
Inventor
Detlef Grawe
Hagen Gerecke
Peter Hoesel
Annette Eichardt
Sabine Gliesing
Uwe Mueller
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of BR0309357A publication Critical patent/BR0309357A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0085—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being a saturated hydrocarbon group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"MéTODO PARA FABRICAR CRISTAIS DE ESTERóIDES, CRISTAIS OBTìVEIS DE ACORDO COM ESSE MéTODO, E FORMULAçõES FARMACêUTICAS". Sendo o tamanho médio de partícula situa-se em uma faixa pré-determinada e cujo tamanho máximo de partícula não ultrapassa um valor pré-determinado, sendo que uma solução supersaturada dos esteróides, é submetida a uma moagem úmida durante a cristalização por meio de um dispositivo para moagem úmida, sendo obtida uma suspensão de grão primário. Além disso, são descritos cristais obtíveis com base nesse método bem como formulações farmacêuticas, que contém esses cristais.
BR0309357-3A 2002-04-23 2003-04-22 Método para fabricar cristais de esteróides, cristais obtìveis de acordo com esse método, e formulações farmacêuticas BR0309357A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10218107A DE10218107A1 (de) 2002-04-23 2002-04-23 Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
PCT/EP2003/004154 WO2003091272A1 (de) 2002-04-23 2003-04-22 Verfahren zum herstellen von kristallen von steroiden, danach erhältliche kristalle und deren verwendung in pharmazeutischen formulierungen

Publications (1)

Publication Number Publication Date
BR0309357A true BR0309357A (pt) 2005-02-22

Family

ID=29264787

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0309357-3A BR0309357A (pt) 2002-04-23 2003-04-22 Método para fabricar cristais de esteróides, cristais obtìveis de acordo com esse método, e formulações farmacêuticas

Country Status (20)

Country Link
US (1) US7148212B2 (pt)
EP (1) EP1497308B1 (pt)
JP (1) JP4490116B2 (pt)
KR (1) KR20040106380A (pt)
CN (1) CN1646555A (pt)
AT (1) ATE340186T1 (pt)
AU (1) AU2003232491A1 (pt)
BR (1) BR0309357A (pt)
CA (1) CA2480004C (pt)
DE (2) DE10218107A1 (pt)
DK (1) DK1497308T3 (pt)
ES (1) ES2274258T3 (pt)
IL (1) IL163986A0 (pt)
MX (1) MXPA04010467A (pt)
NO (1) NO20045023L (pt)
PL (1) PL371340A1 (pt)
PT (1) PT1497308E (pt)
RU (1) RU2315056C2 (pt)
WO (1) WO2003091272A1 (pt)
ZA (1) ZA200409401B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10218109A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
PL1886694T3 (pl) * 2006-08-10 2009-11-30 Jenapharm Gmbh Doustna postać leku do antykoncepcji
US20080038350A1 (en) * 2006-08-10 2008-02-14 Hagen Gerecke Low-dosage peroral medication for contraception containing crystalline dienogest and ethinyl estradiol
DE102008037025C5 (de) * 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
DE102010003711B4 (de) * 2010-04-08 2015-04-09 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoffpartikel
RU2642244C2 (ru) * 2010-04-12 2018-01-24 Кларус Терапеутикс, Инк. Оральные фармацевтические композиции сложных эфиров тестостерона и способы лечения недостатка тестостерона с их использованием
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9745250B2 (en) 2014-05-13 2017-08-29 Akzo Nobel Chemicals International B.V. Process to crystallize chelating agents
JP2020503269A (ja) 2016-11-28 2020-01-30 リポカイン インコーポレーテッド 経口ウンデカン酸テストステロン療法
WO2020018974A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
JP7029875B1 (ja) 2020-05-15 2022-03-04 塩野義製薬株式会社 不純物の生成を抑制した医薬組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3226389A (en) * 1962-01-04 1965-12-28 Du Pont 11,11,12,12-tetracyano-naphtho-2,6-quinodimethan and its anion-radical salts
WO1990003782A2 (en) 1988-10-05 1990-04-19 The Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
DE3917617A1 (de) * 1989-05-31 1990-12-06 Boehringer Ingelheim Kg Mikronisierte bioabbaubare partikel, verfahren zur ihrer herstellung und ihre verwendung
FR2668945B1 (fr) * 1990-11-12 1993-02-19 Theramex Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.
DE69227849T2 (de) 1991-07-10 1999-04-29 Chiyoda Corp., Yokohama Verfahren und Herstellung eines Kristallinadduktes von Bisphenol A mit Phenol und Vorrichtung dafür
NZ248813A (en) * 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
CN1052194C (zh) * 1993-12-27 2000-05-10 日本曹达株式会社 用于彩色显影的含有4-羟基-4'-异丙氧基二苯砜的组合物及其湿性研磨法和分散液
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
WO2000039076A1 (fr) * 1998-12-25 2000-07-06 Fuji Chemical Industries, Ltd. Procede de production de pantothenate de calcium
EP1157996A1 (de) * 2000-05-23 2001-11-28 JENAPHARM GmbH Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on
DE10218109A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen

Also Published As

Publication number Publication date
IL163986A0 (en) 2005-12-18
DE50305122D1 (de) 2006-11-02
ATE340186T1 (de) 2006-10-15
RU2004134324A (ru) 2006-02-10
EP1497308B1 (de) 2006-09-20
KR20040106380A (ko) 2004-12-17
CN1646555A (zh) 2005-07-27
MXPA04010467A (es) 2004-12-13
RU2315056C2 (ru) 2008-01-20
CA2480004A1 (en) 2003-11-06
ES2274258T3 (es) 2007-05-16
WO2003091272A1 (de) 2003-11-06
JP2005524698A (ja) 2005-08-18
EP1497308A1 (de) 2005-01-19
PT1497308E (pt) 2007-01-31
CA2480004C (en) 2007-11-13
DE10218107A1 (de) 2003-11-20
US20030216360A1 (en) 2003-11-20
NO20045023L (no) 2004-11-18
AU2003232491A1 (en) 2003-11-10
US7148212B2 (en) 2006-12-12
PL371340A1 (en) 2005-06-13
JP4490116B2 (ja) 2010-06-23
DK1497308T3 (da) 2007-01-29
ZA200409401B (en) 2006-02-22

Similar Documents

Publication Publication Date Title
BR0309357A (pt) Método para fabricar cristais de esteróides, cristais obtìveis de acordo com esse método, e formulações farmacêuticas
DE60332776D1 (de) Herstellung von Delta-9-Tetrahydrocannabinol
CA2225250A1 (en) Bicyclic amino derivatives and pgd2 antagonist containing the same
SE9903760D0 (sv) New compounds
MX2022016230A (es) Clorhidrato de (s)-(4,5-dihidro-7h-tieno[2,3-c]piran-7-il)-nmetilm etanamina cristalino y formulaciones de las mismas.
MX2007011695A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
BRPI0408369A (pt) derivados de indol úteis para o tratamento de doenças
SE9904176D0 (sv) New use
BR0311494A (pt) Novos indóis substituìdos
BR0007778A (pt) Peptidila cetonas heterocìclicas úteis como inibidores de triptase
SG151254A1 (en) Substituted morpholine and thiomorpholine derivatives
NO902301D0 (no) Fremgangsmaate for fremstilling av diarylstyrylkinolin-disyrer.
BR0307574A (pt) Derivados de nicotinamida úteis como inibidores de pde4
ATE468825T1 (de) Flacher instrumentenhalter
SE423234B (sv) Forfarande for framstellning av den kristallina 2-formen av 2-/4-(2-furoyl)-piperazin-1-yl/-4 amino-6,7-dimetoxi-kinazolinhydroklorid
BR0309358A (pt) Processo para fabricar cristais de substâncias ativas medicinais, cristais obtìveis com base nesse método e formulações farmacêuticas
ES466852A1 (es) Procedimiento para la preparacion de 2-bromo-6-fluor-n-2-i- midazolidinilidenbenzamina.
ATE374195T1 (de) Indazol-3-one und analoga und derivate davon, die die funktion des vanilloid-1-rezeptors (vr1) modulieren
DE3787796D1 (de) Anwendung heterozyklischer Derivate zur Herstellung von Arzneimitteln.
NO864635L (no) Nye krystallinske salter av aryloksypropanolaminer, deres fremstilling og anvendelse.
ATE295845T1 (de) Prucaloprid-n-oxid
NO158803C (no) Analogifremgangsmaate for fremstilling av den terapeutisk aktive forbindelse n-(3-trifluormetylfenyl)-n[-propargylpiperazin.
FI890690A0 (fi) Nya basiskt substituerade 5-halogen-tienoisotiazol-3(2h)-on-1,1-dioxider, foerfarande foer deras framstaellning och dessa foereningar innehaollande farmaceutiska preparat.
AR025901A1 (es) (tio)amidas del acido n-fenil-fenoxinicotinico sustituidas
HUP0004967A2 (en) New crystalline form of nestorone and process for the preparation thereof

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010.